Brevan Howard Capital Management LP Altimmune, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 222,942 shares of ALT stock, worth $929,668. This represents 0.0% of its overall portfolio holdings.
Number of Shares
222,942
Previous 133,209
67.36%
Holding current value
$929,668
Previous $515,000
63.11%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ALT
# of Institutions
195Shares Held
40.1MCall Options Held
3.82MPut Options Held
2.8M-
Vanguard Group Inc Valley Forge, PA6.37MShares$26.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.32MShares$22.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.6MShares$15 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.13MShares$8.89 Million0.37% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$8.41 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $204M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...